Results 271 to 280 of about 1,175,170 (409)

RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management [PDF]

open access: bronze, 2010
Ross M. Fasano   +11 more
openalex   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Monocyte‐Derived Macrophages‐Synovial Fibroblasts Crosstalk Unravels Oncostatin Signaling Network as a Driver of Synovitis in Osteoarthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Osteoarthritis (OA) is a debilitating joint disease that is characterized by cartilage degradation, synovial inflammation, and pain. Macrophages have been implicated in OA pathology, but the origins and functions of diverse macrophage subsets seeding the synovial joint tissue remain incompletely understood.
Damien Laouteouet   +18 more
wiley   +1 more source

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics. [PDF]

open access: yesNat Med
Furer N   +26 more
europepmc   +1 more source

Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.

open access: yesBlood, 2007
M. Yoder   +9 more
semanticscholar   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy